OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 80.32% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2015-09-30 was 64.20%, a 16.30% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2015-06-30 was 66.40%, a 13.43% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2015-03-31 was 72.00%, a 6.49% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2014-09-30 was 76.70%.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2025 was 80.32%, a 0.25% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2024 was 80.12%, a 3.62% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 77.32%, a 4.71% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2022 was 81.14%, a 7.43% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 80.32% 10-K · filed 2026-02-05 | ||||
| 2024-12-31 | 80.12% 10-K · filed 2026-02-05 | ||||
| 2023-12-31 | 77.32% 10-K · filed 2026-02-05 | ||||
| 2022-12-31 | 81.14% 10-K · filed 2025-03-03 | ||||
| 2021-12-31 | 87.65% 10-K · filed 2024-03-11 | ||||
| 2020-12-31 | 86.00% 10-K · filed 2023-03-06 | ||||
| 2019-12-31 | 87.00% 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | 102.00% 10-K · filed 2020-03-12 | ||||
| 2017-12-31 | 102.00% 10-K · filed 2020-03-12 | ||||
| 2016-12-31 | 85.00% 10-K · filed 2019-03-07 | ||||
| 2015-12-31 | 71.00% 10-K · filed 2018-03-08 | 71.10% 10-K · filed 2016-03-10 | |||
| 2015-09-30 | 64.20% 10-Q · filed 2015-11-10 | 71.40% 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | 66.40% 10-Q · filed 2015-08-10 | 71.60% 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | 72.00% 10-Q · filed 2015-05-15 | ||||
| 2014-12-31 | 77.00% 10-K · filed 2017-03-10 | 76.50% 10-K · filed 2015-03-20 | |||
| 2014-09-30 | 76.70% 10-Q · filed 2015-11-10 | 76.50% 10-Q · filed 2015-11-10 | |||
| 2014-06-30 | 76.70% 10-Q · filed 2015-08-10 | 76.50% 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | 77.00% 10-Q · filed 2015-05-15 | ||||
| 2013-12-31 | 74.60% 10-K · filed 2016-03-10 | ||||
| 2012-12-31 | 70.00% 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |